Use of targeted therapy for refractory ALK-positive anaplastic large cell lymphoma as a bridging strategy prior to allogeneic transplantation

被引：19
|
作者：
Ordemann, R. [1 ]
Stoehlmacher, J. [1 ]
Beuthien-Baumann, B. [2 ]
Platzek, I. [2 ]
van den Hoff, J. [3 ]
Kroschinsky, F. [1 ]
Middeke, J. M. [1 ]
Platzbecker, U. [1 ]
Zietz, C. [4 ]
Bornhaeuser, M. [1 ]
Ehninger, G. [1 ]
机构：
[1] Univ Hosp, Med Clin & Policlin 1, D-01307 Dresden, Germany
[2] Univ Hosp, Dept Radiat Oncol, D-01307 Dresden, Germany
[3] Helmholtz Zentrum Dresden Rossendorf, Inst Radiopharm, PET Ctr, D-01314 Dresden, Germany
[4] Univ Hosp, Dept Pathol, D-01307 Dresden, Germany
来源：
ANNALS OF HEMATOLOGY | 2013年 / 92卷 / 01期
关键词：
LUNG-CANCER; CRIZOTINIB;
D O I：
10.1007/s00277-012-1524-0
中图分类号：
R5 [内科学];
学科分类号：
1002 ; 100201 ;
摘要：
引用
收藏
页码：125 / 127
页数：3
相关论文
共 50 条
  • [1] Use of targeted therapy for refractory ALK-positive anaplastic large cell lymphoma as a bridging strategy prior to allogeneic transplantation
    R. Ordemann
    J. Stöhlmacher
    B. Beuthien-Baumann
    I. Platzek
    J. van den Hoff
    F. Kroschinsky
    J. M. Middeke
    U. Platzbecker
    C. Zietz
    M. Bornhäuser
    G. Ehninger
    [J]. Annals of Hematology, 2013, 92 : 125 - 127
  • [2] Anaplastic large cell lymphoma, ALK-positive
    Ferreri, Andres J. M.
    Govi, Silvia
    Pileri, Stefano A.
    Savage, Kerry J.
    [J]. CRITICAL REVIEWS IN ONCOLOGY HEMATOLOGY, 2012, 83 (02) : 293 - 302
  • [3] Alectinib, an anaplastic lymphoma kinase (ALK) inhibitor, as a bridge to allogeneic stem cell transplantation in a patient with ALK-positive anaplastic large-cell lymphoma refractory to chemotherapy and brentuximab vedotin
    Nakai, Ritsuko
    Fukuhara, Suguru
    Maeshima, Akiko Miyagi
    Kim, Sung-Won
    Ito, Yuta
    Hatta, Shunsuke
    Suzuki, Tomotaka
    Yuda, Sayako
    Makita, Shinichi
    Munakata, Wataru
    Suzuki, Tatsuya
    Maruyama, Dai
    Izutsu, Koji
    [J]. CLINICAL CASE REPORTS, 2019, 7 (12): : 2500 - 2504
  • [4] Long-term remission of primary refractory ALK-positive anaplastic large cell lymphoma after allogeneic hematopoietic stem cell transplantation
    Miyazaki, Masahiro
    Ichikawa, Satoshi
    Onishi, Yasushi
    Fukuhara, Noriko
    Furukawa, Eijiro
    Onodera, Koichi
    Yokoyama, Hisayuki
    Ichinohasama, Ryo
    Harigae, Hideo
    [J]. JOURNAL OF CLINICAL AND EXPERIMENTAL HEMATOPATHOLOGY, 2022, 62 (03) : 164 - 168
  • [5] Immune response to ALK in ALK-positive anaplastic large cell lymphoma
    Woessmann, W.
    [J]. BRITISH JOURNAL OF HAEMATOLOGY, 2015, 171 : 23 - 24
  • [6] Refractory ALK-Positive Anaplastic Large Cell Lymphoma: Long Term Survival with Crizotinib
    Ganesan, Prasanth
    Joshua, Thanda
    Sundersingh, Shirley
    Sagar, Tenali Gnana
    [J]. INDIAN JOURNAL OF HEMATOLOGY AND BLOOD TRANSFUSION, 2018, 34 (02) : 353 - 354
  • [7] Refractory or relapsed ALK-positive anaplastic T large cell lymphoma treated with crizotinib
    Miaomiao, L.
    Zhang, M.
    [J]. EUROPEAN JOURNAL OF IMMUNOLOGY, 2019, 49 : 1758 - 1758
  • [8] Refractory ALK-Positive Anaplastic Large Cell Lymphoma: Long Term Survival with Crizotinib
    Prasanth Ganesan
    Thanda Joshua
    Shirley Sundersingh
    Tenali Gnana Sagar
    [J]. Indian Journal of Hematology and Blood Transfusion, 2018, 34 : 353 - 354
  • [9] A Case of Colonic ALK-Positive Anaplastic Large Cell Lymphoma
    Petropolis, Harrison
    Arseneau, Iain
    Blackman, Rachelle
    Fraser, Hughie
    Epstein, Ian
    Anderson, David
    [J]. AMERICAN JOURNAL OF GASTROENTEROLOGY, 2017, 112 : S860 - S861
  • [10] Leukemic phase of ALK-positive anaplastic large cell lymphoma
    He, Rong
    Viswanatha, David S.
    [J]. BLOOD, 2013, 121 (11) : 1934 - 1934
12345